Sudarshan Hebbar

1.0k total citations
17 papers, 490 citations indexed

About

Sudarshan Hebbar is a scholar working on Surgery, Emergency Medicine and Infectious Diseases. According to data from OpenAlex, Sudarshan Hebbar has authored 17 papers receiving a total of 490 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Surgery, 3 papers in Emergency Medicine and 2 papers in Infectious Diseases. Recurrent topics in Sudarshan Hebbar's work include Pancreatitis Pathology and Treatment (4 papers), Endometrial and Cervical Cancer Treatments (2 papers) and COVID-19 Clinical Research Studies (2 papers). Sudarshan Hebbar is often cited by papers focused on Pancreatitis Pathology and Treatment (4 papers), Endometrial and Cervical Cancer Treatments (2 papers) and COVID-19 Clinical Research Studies (2 papers). Sudarshan Hebbar collaborates with scholars based in United States, South Korea and Malaysia. Sudarshan Hebbar's co-authors include Kenneth A. Stauderman, Charles Bruen, Glenn M. Chertow, Colin J. Meyer, Keith W. Ward, Scott A. Reisman, Nosratola D. Vaziri, Walter L. Bender, Richard S. Muther and Chi‐An Chen and has published in prestigious journals such as Stroke, Journal of the American Society of Nephrology and Critical Care Medicine.

In The Last Decade

Sudarshan Hebbar

14 papers receiving 485 citations

Peers

Countries citing papers authored by Sudarshan Hebbar

Since Specialization

Citations

This map shows the geographic impact of Sudarshan Hebbar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sudarshan Hebbar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sudarshan Hebbar more than expected).

Fields of papers citing papers by Sudarshan Hebbar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sudarshan Hebbar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sudarshan Hebbar. The network helps show where Sudarshan Hebbar may publish in the future.

Co-authorship network of co-authors of Sudarshan Hebbar

This figure shows the co-authorship network connecting the top 25 collaborators of Sudarshan Hebbar. A scholar is included among the top collaborators of Sudarshan Hebbar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sudarshan Hebbar. Sudarshan Hebbar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Zegocractin for acute pancreatitis with systemic inflammatory response syndrome: a randomized, controlled, dose-ranging, phase 2b trial 2026 ·EClinicalMedicine ·(unknown), (unknown), (unknown), (unknown), James Buxbaum, (unknown), (unknown), Kenneth A. Stauderman, Sudarshan Hebbar, (unknown), (unknown), (unknown)	0
2	Inhibition of Calcium Release-Activated Calcium Channels to Treat Acute Kidney Injury: Design and Rationale of the KOURAGE Study a Randomized Trial 2025 ·American Journal of Nephrology ·Lakhmir S. Chawla, Patrick Murray, Stuart L. Goldstein, Andrew Cunningham, Sudarshan Hebbar, Richard G. Wunderink, Glenn M. Chertow	0
3	Orai1 calcium channel inhibition prevents progression of chronic pancreatitis 2023 ·JCI Insight ·(unknown), (unknown), (unknown), Tamara Madácsy, Árpád Varga, (unknown), (unknown), (unknown), Tim Crul, (unknown), Mária Bagyánszki, Nikolett Bódi, Ferhan Ayaydin, (unknown), László Tiszlavicz, Kenneth A. Stauderman, Sudarshan Hebbar, Petra Pallagi, József Maléth	14
4	Auxora vs. placebo for the treatment of patients with severe COVID-19 pneumonia: a randomized-controlled clinical trial 2022 ·Critical Care ·Charles Bruen, (unknown), Edward A. Michelson, Maged Tanios, (unknown), Joseph Miller, Jeffrey Zhang, Kenneth A. Stauderman, Sudarshan Hebbar, Peter C. Hou	25
5	Derivation and validation of the ED-SAS score for very early prediction of mortality and morbidity with acute pancreatitis: a retrospective observational study 2021 ·BMC Emergency Medicine ·Joseph Miller, Yiyang Wu, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Ashley Scott, Vidhya Nair, (unknown), (unknown), Sudarshan Hebbar, L.B. Ekstrom	10
6	Auxora for the Treatment of Patients With Acute Pancreatitis and Accompanying Systemic Inflammatory Response Syndrome 2021 ·Pancreas ·Charles Bruen, Joseph Miller, (unknown), Caleb Mackey, Thomas L. Bollen, Kenneth A. Stauderman, Sudarshan Hebbar	44
7	Auxora Improves Outcomes in Patients With Severe COVID-19 Pneumonia: A Randomized Clinical Trial 2021 ·SSRN Electronic Journal ·Charles Bruen, (unknown), Edward A. Michelson, Maged Tanios, (unknown), Joseph Miller, Jeffrey Zhang, Kenneth A. Stauderman, Sudarshan Hebbar, Peter C. Hou, (unknown)	1
8	Auxora versus standard of care for the treatment of severe or critical COVID-19 pneumonia: results from a randomized controlled trial 2020 ·Critical Care ·Joseph M. Miller, Charles Bruen, (unknown), Jeffrey Zhang, Sádia Ali, April Lind, (unknown), Kenneth A. Stauderman, Sudarshan Hebbar	55
9	294: Auxora Improves D-Dimer Levels in Patients With Severe COVID-19 Pneumonia 2020 ·Critical Care Medicine ·Charles Bruen, Joseph Miller, (unknown), Jeffrey Zhang, (unknown), April Lind, (unknown), Kenneth A. Stauderman, Sudarshan Hebbar	1
10	Microglial Calcium Release-Activated Calcium Channel Inhibition Improves Outcome from Experimental Traumatic Brain Injury and Microglia-Induced Neuronal Death 2018 ·Journal of Neurotrauma ·Atsushi Mizuma, Jong Youl Kim, Rachid Kacimi, Ken Stauderman, Michael J. Dünn, Sudarshan Hebbar, Midori A. Yenari	29
11	Abstract TP272: Calcium Release-activated Calcium (CRAC) Channel Inhibition Protects Against Brain Injury and Neuronal Death Induced by Activated Microglia 2017 ·Stroke ·Rachid Kacimi, Jong Youl Kim, Ken Stauderman, Michael J. Dünn, Sudarshan Hebbar, Midori A. Yenari	0
12	Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings 2015 ·Journal of Gynecologic Oncology ·Sarikapan Wilailak, (unknown), Chi‐An Chen, Joo-Hyun Nam, Kazunori Ochiai, Tar Choon Aw, (unknown), Sudarshan Hebbar, (unknown), Beth A. Schodin, Chuenkamon Charakorn, (unknown)	37
13	Prospective Safety Study of Bardoxolone Methyl in Patients with Type 2 Diabetes Mellitus, End-Stage Renal Disease and Peritoneal Dialysis 2012 ·Contributions to nephrology ·David G. Warnock, Sudarshan Hebbar, Joanne M. Bargman, John Burkart, Simon J. Davies, Frederic O. Finkelstein, Rajnish Mehrotra, Claudio Ronco, Isaac Teitelbaum, (unknown), Glenn M. Chertow	4
14	Bardoxolone Methyl Decreases Megalin and Activates Nrf2 in the Kidney 2012 ·Journal of the American Society of Nephrology ·Scott A. Reisman, Glenn M. Chertow, Sudarshan Hebbar, Nosratola D. Vaziri, Keith W. Ward, Colin J. Meyer	82
15	The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass 2012 ·Gynecologic Oncology ·Karen K. L. Chan, Chi‐An Chen, Joo‐Hyun Nam, Kazunori Ochiai, Sarikapan Wilailak, (unknown), (unknown), Sudarshan Hebbar, (unknown), Beth A. Schodin, (unknown)	76
16	Adverse drug reaction driven immunosuppressive drug manipulations: a single‐center comparison of enteric‐coated mycophenolate sodium vs. mycophenolate mofetil 2008 ·Clinical Transplantation ·Karen L. Hardinger, Sudarshan Hebbar, (unknown), Daniel Murillo	18
17	Factors associated with medication-related problems in ambulatory hemodialysis patients 2003 ·American Journal of Kidney Diseases ·Harold J. Manley, (unknown), (unknown), (unknown), (unknown), Walter L. Bender, (unknown), Sudarshan Hebbar, Richard S. Muther	94

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact